Overview

Study of EVX-01 Vaccine in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Status:
Not yet recruiting

Trial end date:
2025-07-25

Target enrollment:

Participant gender:

Summary

The purpose of this single arm, multi-national clinical trial in patients with metastatic or unresectable melanoma is to evaluate the BOR and compare it to historical data on patients on anti-PD1 treatment with pembrolizumab alone.

Phase:

Phase 2

Details

Lead Sponsor:

Evaxion Biotech A/S

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab